ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > class war

<< Previous

Bullboard Posts

Next >>

Comment by M101on Feb 22, 2022 12:11pm

149 Views

Post# 34450540

RE:RE:RE:class war

Gbathat wrote: Probably because the bigger companies are not offering what PMN wants, yet.

And everyone is building in-house AI platforms so until PMN has its first product who's going to fork out the billion(s) that it's worth? I suspect that until then only individual drug licence and JV deals are being shopped. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577280/

<< Previous

Bullboard Posts

Next >>

@ the Bell: TSX advances to start off Christmas trading week